ST Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
ST Pharm makes the active pharmaceutical ingredients used in oligonucleotide therapies, a class of medicines that work by targeting genetic material, and in mRNA-based vaccines and drugs, supplying these materials to pharmaceutical and biotech companies worldwide.
Listed on KOSDAQ, Korea's tech and small-cap board, it also provides contract development and manufacturing services (CDMO) for small-molecule drugs. The company has expanded from small-molecule CDMO into oligonucleotide and mRNA ingredients, and it runs its own drug-discovery pipeline alongside its contract manufacturing business.
Summary is AI-generated and may contain errors · figures from DART filings
ST Pharm is a member of Dong-A Socio Group, a Korean conglomerate, having been brought into the group over a decade ago.
ST Pharm in five facts
What does ST Pharm do?
ST Pharm makes the active pharmaceutical ingredients used in oligonucleotide therapies, a class of medicines that work by targeting genetic material, and in mRNA-based vaccines and drugs, supplying these materials to pharmaceutical and biotech companies worldwide.
Where is ST Pharm listed and in which sector?
ST Pharm (Korean name: 에스티팜) trades under KRX code 237690 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is ST Pharm?
Its market capitalisation was US$1.5B on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were ST Pharm's latest annual revenue and operating profit?
For fiscal year 2025, ST Pharm reported revenue of US$250.3M, operating profit of US$41.5M and net income of US$41.2M, per its annual report on DART (data retrieved from DART on 2026-09-18). Revenue was up 21.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-18
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 8
- DisclosureOct 6
- Report on large shareholdings (5% rule) (abbreviated)Oct 2
- Supply contract signed
ST Pharm disclosed a supply contract, worth US$66.2M, about 27.54% of its recent annual revenue, running through Nov 2027.
Supply contract · Sep 18 - Investor relations (IR) meetingSep 9
- Early redemption of convertible bonds (incl. overseas CBs)
ST Pharm redeemed US$21.2M in face value of its 2nd-series convertible bonds before maturity on 2026-08-10, paying US$21.6M including interest, leaving US$14.9M outstanding.
Capital raise · Aug 11 - Operating results (consolidated) (preliminary) (fair disclosure)
ST Pharm filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$74.1M (+58.9% year on year), operating profit of US$12.5M (+41.7% year on year) and net income of US$8.98M (+145% year on year).
Earnings · Jul 27 - Operating results (consolidated) (preliminary) (fair disclosure)
ST Pharm filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$45.5M (+27.7% year on year), operating profit of US$7.83M (+1024.6% year on year) and net income of US$10.3M (+2044.8% year on year).
Earnings · Apr 27 - [Amended] Cash/in-kind dividend decision
ST Pharm updated its declared cash dividend of US$0.34 per share, equal to about 0.3% of the recent share price.
Dividend · Apr 21 · 2 versions - Supply contract signed
ST Pharm disclosed a supply contract, worth US$59.8M, about 32.8% of its recent annual revenue, running through Nov 2027.
Supply contract · Mar 16 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
ST Pharm reported consolidated results for FY2025: revenue of US$228M (+21.2% year on year), operating profit of US$37.9M (+99.4% year on year) and net income of US$37.5M (+68.2% year on year).
Earnings · Feb 11 - Operating results (consolidated) (preliminary) (fair disclosure)
ST Pharm filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$88.2M (+11.4% year on year), operating profit of US$18.1M (+15.9% year on year) and net income of US$21.2M (+148.9% year on year).
Earnings · Feb 9 - Supply contract signedSupply contract · Jan 23